GW&K Investment Management LLC Raises Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

GW&K Investment Management LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 139.0% in the third quarter, HoldingsChannel.com reports. The fund owned 1,150,169 shares of the biopharmaceutical company’s stock after acquiring an additional 668,881 shares during the quarter. GW&K Investment Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $34,597,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of RARE. Covestor Ltd lifted its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 369 shares during the period. Huntington National Bank raised its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares during the last quarter. Teacher Retirement System of Texas raised its position in Ultragenyx Pharmaceutical by 1.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after buying an additional 404 shares during the last quarter. Xponance Inc. lifted its stake in Ultragenyx Pharmaceutical by 3.1% during the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock valued at $406,000 after acquiring an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 434 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RARE has been the subject of several recent research reports. Wedbush reissued a “neutral” rating and set a $25.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. Jefferies Financial Group reduced their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. Robert W. Baird decreased their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group reduced their price target on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $68.29.

Insider Activity

In related news, EVP Karah Herdman Parschauer sold 8,135 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $185,478.00. Following the sale, the executive vice president owned 76,346 shares of the company’s stock, valued at approximately $1,740,688.80. This trade represents a 9.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 54,404 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at approximately $15,025,063.20. The trade was a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 108,039 shares of company stock worth $2,506,945. Insiders own 5.50% of the company’s stock.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Regulatory/procedural deadline — multiple firms are reminding eligible purchasers of the April 6, 2026 lead plaintiff deadline for the class action; this is a procedural notice but focuses attention on potential litigation exposure. ROSEN Deadline Notice
• Negative Sentiment: Class action filings and widespread solicitations — multiple law firms (Pomerantz, Robbins Geller, ClaimsFiler, Bronstein Gewirtz & others) have circulated notices and at least one suit has been filed alleging misstatements/omissions tied to setrusumab results; that raises potential legal and financial risk. Pomerantz Notice
• Negative Sentiment: Legal overhang amplified by media/legal alerts — additional reminders from ClaimsFiler, Robbins LLP, Furuqi & Furuqi and others increase publicity around the suit and the potential damages/settlement risk. ClaimsFiler Alert
• Negative Sentiment: Prior clinical setback cited by plaintiff counsel — Levi & Korsinsky highlights the company’s >40% decline after a Phase III setrusumab failure disclosure, framing the litigation narrative and reinforcing investor concern about program and disclosure risk. Levi & Korsinsky Alert
• Negative Sentiment: Insider selling — CFO Howard Horn disclosed multiple recent sales (including March 3 sale of 1,635 shares), feeding short‑term sentiment pressure even if not necessarily signaling company fundamentals. Insider Trades Report

Ultragenyx Pharmaceutical Stock Down 1.6%

NASDAQ:RARE opened at $21.46 on Friday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $42.37. The stock’s 50-day moving average price is $23.30 and its 200-day moving average price is $29.14. The stock has a market capitalization of $2.07 billion, a PE ratio of -3.67 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analysts’ expectations of $199.60 million. During the same quarter in the prior year, the company posted ($1.39) EPS. The business’s revenue for the quarter was up 25.5% compared to the same quarter last year. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.